Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Modulation of c-kit expression in pancreatic adenocarcinoma: a novel stem cell marker responsible for the progression of the disease.

Amsterdam A, Raanan C, Polin N, Melzer E, Givol D, Schreiber L.

Acta Histochem. 2014 Jan;116(1):197-203. doi: 10.1016/j.acthis.2013.07.002. Epub 2013 Aug 23.

PMID:
23978330
2.

LGR5 and Nanog identify stem cell signature of pancreas beta cells which initiate pancreatic cancer.

Amsterdam A, Raanan C, Schreiber L, Polin N, Givol D.

Biochem Biophys Res Commun. 2013 Apr 5;433(2):157-62. doi: 10.1016/j.bbrc.2013.02.038. Epub 2013 Feb 21.

PMID:
23438436
3.

Differential localization of LGR5 and Nanog in clusters of colon cancer stem cells.

Amsterdam A, Raanan C, Schreiber L, Freyhan O, Fabrikant Y, Melzer E, Givol D.

Acta Histochem. 2013 May;115(4):320-9. doi: 10.1016/j.acthis.2012.09.003. Epub 2012 Oct 23.

PMID:
23098761
4.

Localization of the stem cell markers LGR5 and Nanog in the normal and the cancerous human ovary and their inter-relationship.

Amsterdam A, Raanan C, Schreiber L, Freyhan O, Schechtman L, Givol D.

Acta Histochem. 2013 May;115(4):330-8. doi: 10.1016/j.acthis.2012.09.004. Epub 2012 Oct 23.

PMID:
23092806
5.

p53 reactivation: the link to zinc.

D'Orazi G, Givol D.

Cell Cycle. 2012 Jul 15;11(14):2581-2. doi: 10.4161/cc.21020. Epub 2012 Jul 15. No abstract available.

6.

HIPK2 downregulates vimentin and inhibits breast cancer cell invasion.

Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, Garufi A, Rechavi G, Givol D, D'Orazi G.

Cancer Biol Ther. 2012 Feb 15;13(4):198-205. doi: 10.4161/cbt.13.4.18694. Epub 2012 Feb 15.

PMID:
22236966
7.

Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation.

Sheffer M, Simon AJ, Jacob-Hirsch J, Rechavi G, Domany E, Givol D, D'Orazi G.

Oncotarget. 2011 Dec;2(12):1191-202.

8.

Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function.

Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, Rechavi G, D'Orazi G, Givol D, Amariglio N.

Int J Cancer. 2012 Aug 15;131(4):E562-8. doi: 10.1002/ijc.26441. Epub 2011 Nov 30.

9.

Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.

Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, Givol D, D'Orazi G.

Cell Cycle. 2011 May 15;10(10):1679-89. Epub 2011 May 15.

PMID:
21508668
10.

Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo.

Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, Leonetti C, Safran M, Rechavi G, Givol D, Farsetti A, D'Orazi G.

PLoS One. 2010 Dec 13;5(12):e15048. doi: 10.1371/journal.pone.0015048.

11.

Counteracting MDM2-induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells.

Nardinocchi L, Puca R, Givol D, D'Orazi G.

FEBS Lett. 2010 Oct 8;584(19):4253-8. doi: 10.1016/j.febslet.2010.09.018. Epub 2010 Sep 16.

12.

Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.

Puca R, Nardinocchi L, Givol D, D'Orazi G.

Oncogene. 2010 Aug 5;29(31):4378-87. doi: 10.1038/onc.2010.183. Epub 2010 May 31. Review.

PMID:
20514025
13.

HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition.

Nardinocchi L, Puca R, Givol D, D'Orazi G.

Cell Cycle. 2010 Apr 1;9(7):1270-5. Review.

PMID:
20234185
14.

Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors.

Yakubov E, Rechavi G, Rozenblatt S, Givol D.

Biochem Biophys Res Commun. 2010 Mar 26;394(1):189-93. doi: 10.1016/j.bbrc.2010.02.150. Epub 2010 Feb 25.

PMID:
20188704
15.

Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis.

Puca R, Nardinocchi L, Starace G, Rechavi G, Sacchi A, Givol D, D'Orazi G.

Free Radic Biol Med. 2010 May 15;48(10):1338-46. doi: 10.1016/j.freeradbiomed.2010.02.015. Epub 2010 Feb 18.

PMID:
20171273
16.

HIPK2 modulates p53 activity towards pro-apoptotic transcription.

Puca R, Nardinocchi L, Sacchi A, Rechavi G, Givol D, D'Orazi G.

Mol Cancer. 2009 Oct 14;8:85. doi: 10.1186/1476-4598-8-85.

17.

Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.

Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G.

PLoS One. 2009 Aug 28;4(8):e6819. doi: 10.1371/journal.pone.0006819.

18.

PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop.

Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, Blandino G.

Mol Cell. 2008 Dec 26;32(6):803-14. doi: 10.1016/j.molcel.2008.11.019.

19.

Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.

Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D, D'Orazi G.

Exp Cell Res. 2009 Jan 1;315(1):67-75. doi: 10.1016/j.yexcr.2008.10.018. Epub 2008 Oct 28.

PMID:
18996371
20.

FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.

Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bükülmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I, Warman ML, Givol D, Murakami S.

Hum Mol Genet. 2009 Jan 15;18(2):227-40. doi: 10.1093/hmg/ddn339. Epub 2008 Oct 15.

21.

MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells.

Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N, Rechavi G, Givol D.

Biochem Biophys Res Commun. 2008 Nov 7;376(1):86-90. doi: 10.1016/j.bbrc.2008.08.107. Epub 2008 Aug 31.

PMID:
18765229
22.

Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.

Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, Blandino G, Givol D, D'Orazi G.

Cancer Res. 2008 May 15;68(10):3707-14. doi: 10.1158/0008-5472.CAN-07-6776.

23.

Nanog inhibits the switch of myogenic cells towards the osteogenic lineage.

Kochupurakkal BS, Sarig R, Fuchs O, Piestun D, Rechavi G, Givol D.

Biochem Biophys Res Commun. 2008 Jan 25;365(4):846-50. Epub 2007 Nov 26.

PMID:
18039466
24.

Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53.

Weizer-Stern O, Adamsky K, Margalit O, Ashur-Fabian O, Givol D, Amariglio N, Rechavi G.

Br J Haematol. 2007 Jul;138(2):253-62.

PMID:
17593032
25.

A rapid assay for drug sensitivity of glioblastoma stem cells.

Gal H, Makovitzki A, Amariglio N, Rechavi G, Ram Z, Givol D.

Biochem Biophys Res Commun. 2007 Jul 6;358(3):908-13. Epub 2007 May 11.

PMID:
17512905
26.

Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells.

Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D.

Leukemia. 2006 Dec;20(12):2147-54. Epub 2006 Oct 12.

PMID:
17039238
27.

Nanog transforms NIH3T3 cells and targets cell-type restricted genes.

Piestun D, Kochupurakkal BS, Jacob-Hirsch J, Zeligson S, Koudritsky M, Domany E, Amariglio N, Rechavi G, Givol D.

Biochem Biophys Res Commun. 2006 Apr 28;343(1):279-85. Epub 2006 Mar 6.

PMID:
16540082
28.

S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation.

Lapi E, Iovino A, Fontemaggi G, Soliera AR, Iacovelli S, Sacchi A, Rechavi G, Givol D, Blandino G, Strano S.

Oncogene. 2006 Jun 22;25(26):3628-37. Epub 2006 Jan 30.

PMID:
16449968
29.

The UVB-induced gene expression profile of human epidermis in vivo is different from that of cultured keratinocytes.

Enk CD, Jacob-Hirsch J, Gal H, Verbovetski I, Amariglio N, Mevorach D, Ingber A, Givol D, Rechavi G, Hochberg M.

Oncogene. 2006 Apr 27;25(18):2601-14.

PMID:
16434974
30.

BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma.

Margalit O, Amram H, Amariglio N, Simon AJ, Shaklai S, Granot G, Minsky N, Shimoni A, Harmelin A, Givol D, Shohat M, Oren M, Rechavi G.

Blood. 2006 Feb 15;107(4):1599-607. Epub 2005 Oct 25.

31.

CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia.

Toren A, Bielorai B, Jacob-Hirsch J, Fisher T, Kreiser D, Moran O, Zeligson S, Givol D, Yitzhaky A, Itskovitz-Eldor J, Kventsel I, Rosenthal E, Amariglio N, Rechavi G.

Stem Cells. 2005 Sep;23(8):1142-53.

32.

Vascular gene expression and phenotypic correlation during differentiation of human embryonic stem cells.

Gerecht-Nir S, Dazard JE, Golan-Mashiach M, Osenberg S, Botvinnik A, Amariglio N, Domany E, Rechavi G, Givol D, Itskovitz-Eldor J.

Dev Dyn. 2005 Feb;232(2):487-97.

33.

Design principle of gene expression used by human stem cells: implication for pluripotency.

Golan-Mashiach M, Dazard JE, Gerecht-Nir S, Amariglio N, Fisher T, Jacob-Hirsch J, Bielorai B, Osenberg S, Barad O, Getz G, Toren A, Rechavi G, Itskovitz-Eldor J, Domany E, Givol D.

FASEB J. 2005 Jan;19(1):147-9. Epub 2004 Oct 21.

PMID:
15498892
34.

Outcome signature genes in breast cancer: is there a unique set?

Ein-Dor L, Kela I, Getz G, Givol D, Domany E.

Bioinformatics. 2005 Jan 15;21(2):171-8. Epub 2004 Aug 12.

PMID:
15308542
35.
36.

Hair growth induction by the Tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression.

Sredni B, Gal R, Cohen IJ, Dazard JE, Givol D, Gafter U, Motro B, Eliyahu S, Albeck M, Lander HM, Kalechman Y.

FASEB J. 2004 Feb;18(2):400-2. Epub 2003 Dec 4.

PMID:
14656992
37.

Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer.

Dazard JE, Gal H, Amariglio N, Rechavi G, Domany E, Givol D.

Oncogene. 2003 May 15;22(19):2993-3006.

PMID:
12771951
38.

Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes.

Lotem J, Gal H, Kama R, Amariglio N, Rechavi G, Domany E, Sachs L, Givol D.

Proc Natl Acad Sci U S A. 2003 May 27;100(11):6718-23. Epub 2003 May 12.

39.

Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses.

Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, Sacchi A, Givol D, Blandino G.

J Biol Chem. 2002 Nov 8;277(45):43359-68. Epub 2002 Sep 3.

40.

A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1.

Rozenfeld-Granot G, Krishnamurthy J, Kannan K, Toren A, Amariglio N, Givol D, Rechavi G.

Oncogene. 2002 Feb 28;21(10):1469-76.

41.

Apoptosis of granulosa cells and female infertility in achondroplastic mice expressing mutant fibroblast growth factor receptor 3G374R.

Amsterdam A, Kannan K, Givol D, Yoshida Y, Tajima K, Dantes A.

Mol Endocrinol. 2001 Sep;15(9):1610-23.

PMID:
11518810
42.

DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1.

Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D.

Oncogene. 2001 Jun 7;20(26):3449-55.

43.

DNA microarrays identification of primary and secondary target genes regulated by p53.

Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D.

Oncogene. 2001 Apr 26;20(18):2225-34.

44.
45.

Profile of gene expression regulated by induced p53: connection to the TGF-beta family.

Kannan K, Amariglio N, Rechavi G, Givol D.

FEBS Lett. 2000 Mar 17;470(1):77-82.

46.

Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice.

Segev O, Chumakov I, Nevo Z, Givol D, Madar-Shapiro L, Sheinin Y, Weinreb M, Yayon A.

Hum Mol Genet. 2000 Jan 22;9(2):249-58.

PMID:
10607835
47.

H2O2-induced apoptotic death in serum-deprived cultures of oligodendroglia origin is linked to cell differentiation.

Kameshwar-Rao AS, Gil S, Richter-Landsberg C, Givol D, Yavin E.

J Neurosci Res. 1999 Jun 1;56(5):447-56.

PMID:
10369212
49.

A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.

Wang Y, Spatz MK, Kannan K, Hayk H, Avivi A, Gorivodsky M, Pines M, Yayon A, Lonai P, Givol D.

Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4455-60.

Supplemental Content

Support Center